ForwardHealth advises prescribers to be mindful of the continuing manufacturer shortages for anti-obesity drugs Saxenda, Wegovy, and Zepbound and the role of these medications in weight management. Glucagon-like peptide and gastric inhibitory polypeptide receptor agonist anti-obesity drugs Saxenda, Wegovy, and Zepbound are indicated to be used as an adjunct to diet and physical activity for weight management.
Since prior authorization (PA) requests for members have effective dates, ForwardHealth advises during this drug shortage that prescribers not initiate a new PA request for Saxenda, Wegovy, or Zepbound unless it has been determined that the requested anti-obesity drug is available for the member through a specific pharmacy.
ForwardHealth appreciates your concern and attention to this issue.
For more information about the current PA policy for anti-obesity drugs, prescribers may refer to the Anti-Obesity Drugs topic (#7837) in the ForwardHealth Online Handbook.
Because you have not recently performed an action that loads or reloads a page, your session will expire in Upon expiration your unsaved data will be lost and you will be required to login again to begin a new session. To avoid a session expiration, click this button to extend your session.
Extend